B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad maintains a Buy rating on Amicus Therapeutics and raises the price target from $13 to $15.
October 17, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities has reaffirmed its Buy rating on Amicus Therapeutics and increased the price target from $13 to $15, indicating a positive outlook.
The reaffirmation of a Buy rating and an increase in the price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100